ETC Blog

What do ocean-going yachts, space-traveling bacteria and synthetic life have in common? J. Craig Venter, of course. The self-styled genome tycoon has been busy pushing the boundaries on what may appear at first glance to be unrelated enterprises. Nothing could be further from the truth. A suite of recently uncovered patent applications lodged by Venter and his colleagues reveal not only an attempt to grab ownership over much of synthetic biology (see news release) but also a breathtakingly bold business plan for producing millions of new synthetic organisms per day. At the heart of this are plans for a new, automated process enabling rapid assembly of complete synthetic genomes – plans that, if realised, could render current genetic engineering techniques quaint and obsolete. Venter calls it “homologous in vitro recombination” or “combinatorial genomics.” ETC suggests it might be properly dubbed “shotgun synthesis” and it has the potential to blast apart current biotech practice.

Read the rest of this entry

The BP-Berkeley deal, the new joint Bio Energy institute, and also the recent job hop by John Menlo of BP fuels to Amyris Biotech – are all extra strings tying the interests of the Syn Bio community as a wholeever closer to the interests of big business. It should be noted that in each of thse cases CEO Keasling plays a central role. The same man who claims to be developing Synthetic Biology to serve the worlds poor (via synthetic artemisinin) seems to be rather busy these days serving the fabulously rich.

Read the rest of this entry

“I think this is going to become the foundational technology of the 21st century” – that was the triumphant message with which Tom Knight of MIT brought Synthetic Biology 3.0 to an end today. An engineering generalist who moved from artificial intelligence to artificial life, it was Knight who, along with Drew Endy, developed the [...]

Read the rest of this entry

‘The cool’ and ‘the concerned’ – that was how Zurich-based ethicist Nicola Biller Andorno today aptly characterised the two tribes attending Synthetic Biology 3.0…The cool, in her lexicon, are the synthusiasts, those who regard making synthetic life forms as…like…hey dude, that’s like, so cool. The concerned, roughly speaking, is made up of people like us [...]

Read the rest of this entry

Sunday afternoon and Synthetic Biology 3.0 gets underway in high spirits amidst the glass and concrete of the ETH Campus. Host Sven Panke kicked off the conference promising that SynBio3.0 would have something for everyone — the enthusiasts (clearly the majority), the curious and the skeptics (we guess that’s us). This was clearly the day [...]

Read the rest of this entry

Some of us from ETC are in Zurich for the next few days observing what happens when you cram several hundred synthetic biologists and industrialists into a conference room — the evolution of a new industrial species? These ‘Synthusiasts’ are now into their third annual international congress, Synthetic Biology 3.0, each conference named like a [...]

Read the rest of this entry

Is Craig Venter, the so called “bad boy of biology”, about to announce the world’s first synthetic lifeform? (or ‘Syn’ for short)… we don’t know. According to New Scientist “rumours are circulating that his institute will soon unveil the first synthetic bacterium”. What we do know is that he has applied for a patent with broad claims that include a synthetic organism itself…

Read the rest of this entry

As well as dealing with Monsanto in Munich this week, ETC Group has also been raising the alarm about a massive geo-engineering experiment scheduled for this month around Galapagos by Planktos Inc. Here is an open reply to a public attack on our press release.

Read the rest of this entry

On October 10, ETC Group attended the US Food and Drug Administration’s first public meeting on nanotechnology. About 40 people had signed up to make presentations, and we were each given eight minutes to say our piece to the FDA’s newly-formed Nanotechnology Task Force. (You can read the text of ETC Group’s presentation here.) It [...]

Read the rest of this entry

Nano-Drug’s Dirty Little Secret ETC Group’s September 2006 report on nanomedicine, Nanotech Rx, requires some updating. After all, it’s nearly 30 days old. Our report mentions the nano-drug Abraxane, and it acknowledges that approval of the cancer drug was a watershed event for the nanotech industry. But important details are emerging. On October 1 the [...]

Read the rest of this entry